Abstract
Up to now a treatment decision for patients with MDS is complicated due to the variable natural history, the advanced age and paucity of controlled clinical trials [1]. Although it has often been stated in the literature [2–4] that intensive chemotherapy produces poor results in many MDS patients, although among MDS patients there are some with RAEB/RAEB-T who seem to benefit from such treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Noel P (1991) Management of patients with myelodysplastic syndromes Mayo Clin Proc 66: 485–497
Aul C, Schneider W (1989) The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64: 1812–1818
Fenaux P, Lai JL, Jouet JP, Pollet JP, Bauters F (1988) Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57: 297–302
Preisler HD, Raza A, Barcos M (1986) High-dose cytosine arabinoside in the treatment of preleukemic disorders. AM J Hematology 23: 131–134
Witte De T, Muus P, Pauw De B, Haanen C (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute leukemia. Cancer 66: 831–837
Yunis JJ, Rydell RE, Oken MM, Arnesen MA, Mayer MG, Lobell M (1986) Refined chromosomal analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 67: 1721–1730
Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen Grethe Byrsting K (1990) Chromosome aberrations and prognostic factors in therapyrelated myelodysplasia and acute nonlymphatic leukemia. Blood 76: 1083–1091
Raymakers R, Witte De T, Joziasse J, Lely van der N, Boezeman J, Haanen C (1991) In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphatic leukaemia. British J Haem 78: 35–41
Sauer H, Wilmanns W (1983) Thymidine kinase. ATP: thymidine 5′-phosphotransferase EC 2.7.1.21. In Bergmeyer HU (ed.): Methods of enzymatic analysis. Verlag Chemie, Weinheim, Vol. III: 468–474
Pelka-Fleischer R, Fleischer W, Wilmanns W, Sauer H, Schalhorn A (1989) Relation between cell cycle stage and the activity of DNA-synthesizing enzymes in cultured human lymphoblasts: Investigation on cells separated according to DNA content by way of a cell sorter. Leukemia 3: 380–385
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. British J Haem 51: 189–199
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Nuessler, V., Wilmanns, W., Sauer, H., Pelka-Fleischer, R., Zwierzina, H. (1994). Thymidine Kinase Activity in Bone Marrow Cells as Basis for Rational Treatment of Myelodysplastic Syndromes. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_113
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_113
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive